Alterations in protein expression patterns of spinal peroxisome proliferator-activated receptors after spinal cord injury

References

• Abbott BD. Review of the expression of peroxisome proliferator-activated receptors alpha (PPARα), beta (PPARβ), and gamma (PPARγ) in rodent and human development. Reprod Toxicol. 2009;27:246–257.
   PubMed Web of Science ®Google Scholar
• Tyagi S, Gupta P, Saini AS, et al. The peroxisome proliferator-activated receptor: a family of nuclear receptors role in various diseases. J Adv Pharm Technol Res. 2011;2:236–240.
   PubMedGoogle Scholar
• Schupp M, Lazar MA. Endogenous ligands for nuclear receptors: digging deeper. J Biol Chem. 2010;285:40409–40415.
   PubMed Web of Science ®Google Scholar
• Park SW, Yi JH, Miranpuri G, et al. Thiazolidinedione class of peroxisome proliferator-activated receptor gamma agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, and inflammation after spinal cord injury in adult rats. J Pharmacol Exp Ther. 2007;320:1002–1012.
   PubMed Web of Science ®Google Scholar
• Li X, Du J, Xu S, et al. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces secondary damage in experimental spinal cord injury. J Int Med Res. 2013;41:153–161.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Hu W, Meng B, et al. PPAR gamma agonist rosiglitazone is neuroprotective after traumatic spinal cord injury via anti-inflammatory in adult rats. Neurol Res. 2010;32:852–859.
   PubMed Web of Science ®Google Scholar
• McTigue DM, Tripathi R, Wei P, et al. The PPAR gamma agonist pioglitazone improves anatomical and locomotor recovery after rodent spinal cord injury. Exp Neurol. 2007;205:396–406.
   PubMed Web of Science ®Google Scholar
• Almad A, Lash AT, Wei P, et al. The PPAR alpha agonist gemfibrozil is an ineffective treatment for spinal cord injured mice. Exp Neurol. 2011;232:309–317.
   PubMed Web of Science ®Google Scholar
• Genovese T, Esposito E, Mazzon E, et al. PPAR-alpha modulate the anti-inflammatory effect of glucocorticoids in the secondary damage in experimental spinal cord trauma. Pharmacol Res. 2009;59:338–350.
   PubMed Web of Science ®Google Scholar
• Paterniti I, Esposito E, Mazzon E, et al. Evidence for the role of peroxisome proliferator-activated receptor-beta/delta in the development of spinal cord injury. J Pharmacol Exp Ther. 2010;333:465–477.
   PubMed Web of Science ®Google Scholar
• Michalik L, Wahli W. Involvement of PPAR nuclear receptors in tissue injury and wound repair. J Clin Investig. 2006;116:598–606.
   PubMed Web of Science ®Google Scholar
• Sundararajan S, Gamboa JL, Victor NA, et al. Peroxisome proliferator-activated receptor-γ ligands reduce inflammation and infarction size in transient focal ischemia. Neuroscience. 2005;130:685–696.
   PubMed Web of Science ®Google Scholar
• Wu JS, Cheung WM, Tsai YS, et al. Ligand-activated peroxisome proliferator-activated receptor-gamma protects against ischemic cerebral infarction and neuronal apoptosis by 14-3-3 is an element of upregulation. Circulation. 2009;119:1124–1134.
   PubMed Web of Science ®Google Scholar
• Zhao X, Strong R, Zhang J, et al. Neuronal PPARgamma deficiency increases susceptibility to brain damage after cerebral ischemia. J Neurosci. 2009;29:6186–6195.
   PubMed Web of Science ®Google Scholar
• Romero-Calvo I, Ocon B, Martinez-Moya P, et al. Reversible ponceau staining as a loading control alternative to actin in Western blots. Anal Biochem. 2010;401:318–320.
   PubMed Web of Science ®Google Scholar
• Di Giovanni S, De Biase A, Yakovlev A, et al. In vivo and in vitro characterization of novel neuronal plasticity factors identified following spinal cord injury. J Biol Chem. 2005;280:2084–2091.
   PubMed Web of Science ®Google Scholar
• Liu NK, Xu XM. beta-tubulin is a more suitable internal control than beta-actin in Western blot analysis of spinal cord tissues after traumatic injury. J Neurotrauma. 2006;23:1794–1801.
   PubMed Web of Science ®Google Scholar
• Fajas L, Auboeuf D, Raspé E, et al. The organization, promoter analysis, and expression of the human PPARγ gene. J Biol Chem. 1997;272:18779–18789.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Qi C, Korenberg JR, et al. Structural organization of mouse peroxisome proliferator-activated receptor gamma (mPPAR gamma) gene: alternative promoter use and different splicing yield two mPPAR gamma isoforms. Proc Natl Acad Sci USA. 1995;92:7921–7925.
   PubMed Web of Science ®Google Scholar
• Arsenijevic D, de Bilbao F, Plamondon J, et al. Increased infarct size and lack of hyperphagic response after focal cerebral ischemia in peroxisome proliferator-activated receptor β-deficient mice. J Cereb Blood Flow Metab. 2006;26:433–445.
   PubMed Web of Science ®Google Scholar
• Esposito E, Rinaldi B, Mazzon E, et al. Anti-inflammatory effect of simvastatin in an experimental model of spinal cord trauma: involvement of PPAR-alpha. J Neuroinflammation. 2012;9:81.
   PubMed Web of Science ®Google Scholar
• Cizkova D, Le Marrec-Croq F, Franck J, et al. Alterations of protein composition along the rostro-caudal axis after spinal cord injury: proteomic, in vitro and in vivo analyses. Front Cell Neurosci. 2014;8(105):1-15.
   Web of Science ®Google Scholar
• Devaux S, Cizkova D, Quanico J, et al. Proteomic analysis of the spatio-temporal based molecular kinetics of acute spinal cord injury identifies a time- and segment-specific window for effective tissue repair. Mol Cell Proteomics. 2016;15:2641–2670.
   PubMed Web of Science ®Google Scholar
• Grygiel-Gorniak B. Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications–a review. J Nutr. 2014;13:17.
   Web of Science ®Google Scholar
• Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med. 2002;53:409–435.
   PubMed Web of Science ®Google Scholar
• Qi C, Zhu Y, Reddy JK. Peroxisome proliferator-activated receptors, coactivators, and downstream targets. Cell Biochem Biophys. 2000 Spring;32:187–204.
   PubMed Web of Science ®Google Scholar
• Donnelly DJ, Popovich PG. Inflammation and its role in neuroprotection, axonal regeneration and functional recovery after spinal cord injury. Exp Neurol. 2008;209:378–388.
   PubMed Web of Science ®Google Scholar
• Fleming JC, Norenberg MD, Ramsay DA, et al. The cellular inflammatory response in human spinal cords after injury. Brain. 2006;129:3249–3269.
   PubMed Web of Science ®Google Scholar
• O’Shea TM, Burda JE, Sofroniew MV. Cell biology of spinal cord injury and repair. J Clin Invest. 2017;127:3259–3270.
   PubMed Web of Science ®Google Scholar
• Gelinas DS, McLaurin J. PPAR-α expression inversely correlates with inflammatory cytokines IL-1β and TNF-α in aging rats. Neurochem Res. 2005;30:1369–1375.
   PubMed Web of Science ®Google Scholar
• Paukkeri EL, Leppanen T, Sareila O, et al. PPARalpha agonists inhibit nitric oxide production by enhancing iNOS degradation in LPS-treated macrophages. Br J Pharmacol. 2007;152:1081–1091.
   PubMed Web of Science ®Google Scholar
• Lefebvre P, Chinetti G, Fruchart JC, et al. Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J Clin Investig. 2006;116:571–580.
   PubMed Web of Science ®Google Scholar
• Genovese T, Mazzon E, Di Paola R, et al. Role of endogenous ligands for the peroxisome proliferators activated receptors alpha in the secondary damage in experimental spinal cord trauma. Exp Neurol. 2005;194:267–278.
   PubMed Web of Science ®Google Scholar
• Gonzalez FJ. Recent update on the PPAR alpha-null mouse. Biochimie. 1997;79:139–144.
   PubMed Web of Science ®Google Scholar
• Deloach A, Waggoner GR, Kiaei M, et al. Preferential PPAR-α activation reduces neuroinflammation, and blocks neurodegeneration in vivo. Hum Mol Genet. 2015;25:317–327.
   PubMed Web of Science ®Google Scholar
• Ishihara Y, Itoh K, Ishida A, et al. Selective estrogen-receptor modulators suppress microglial activation and neuronal cell death via an estrogen receptor-dependent pathway. J Steroid Biochem Mol Biol. 2015;145:85–93.
   PubMed Web of Science ®Google Scholar
• Sheridan GK, Murphy KJ. Neuron–glia crosstalk in health and disease: fractalkine and CX(3)CR1 take centre stage. Open Biol. 2013;3:130181.
   PubMed Web of Science ®Google Scholar
• Narala VR, Adapala RK, Suresh MV, et al. Leukotriene B4 is a physiologically relevant endogenous peroxisome proliferator-activated receptor-alpha agonist. J Biol Chem. 2010;285:22067–22074.
   PubMed Web of Science ®Google Scholar
• Devchand PR, Keller H, Peters JM, et al. The PPAR[alpha]-leukotriene B4 pathway to inflammation control. Nature. 1996;384:39–43.
   PubMed Web of Science ®Google Scholar
• Smith U, Gogg S, Johansson A, et al. Thiazolidinediones (PPARgamma agonists) but not PPAR alpha agonists increase IRS-2 gene expression in 3T3-L1 and human adipocytes. Faseb J. 2001;15:215–220.
   PubMed Web of Science ®Google Scholar
• Kim HI, Ahn YH. Role of peroxisome proliferator-activated receptor-gamma in the glucose-sensing apparatus of liver and beta-cells. Diabetes. 2004;53(Suppl 1):S60–S65.
   PubMed Web of Science ®Google Scholar
• Cao Y, Wu T, Yuan Z, et al. Three-dimensional imaging of microvasculature in the rat spinal cord following injury. Sci Rep. 2015;5:12643.
   PubMed Web of Science ®Google Scholar
• Dello Russo C, Gavrilyuk V, Weinberg G, et al. Peroxisome proliferator-activated receptor γ thiazolidinedione agonists increase glucose metabolism in astrocytes. J Biol Chem. 2003;278:5828–5836.
   PubMed Web of Science ®Google Scholar
• Kim Y, Park Y-K, Cho H-Y, et al. Long-term changes in expressions of spinal glutamate transporters after spinal cord injury. Brain Res. 2011;1389:194–199.
   PubMed Web of Science ®Google Scholar
• Kim Y, Cho HY, Ahn YJ, et al. Effect of NMDA NR2B antagonist on neuropathic pain in two spinal cord injury models. Pain. 2012;153:1022–1029.
   PubMed Web of Science ®Google Scholar
• Rawe SE, Lee WA, Perot PL. Spinal cord glucose utilization after experimental spinal cord injury. J Neurosurg. 1981;9:40–47.
   Google Scholar
• Chen H, Shi R, Luo B, et al. Macrophage peroxisome proliferator-activated receptor gamma deficiency delays skin wound healing through impairing apoptotic cell clearance in mice. Cell Death Dis. 2015;6:e1597.
   PubMed Web of Science ®Google Scholar
• Luquet S, Gaudel C, Holst D, et al. Roles of PPAR delta in lipid absorption and metabolism: a new target for the treatment of type 2 diabetes. Biochim Biophys Acta. 2005;1740:313–317.
   PubMed Web of Science ®Google Scholar
• Potthoff MJ, Olson EN, Bassel-Duby R. Skeletal muscle remodeling. Curr Opin Rheumatol. 2007;19:542–549.
   PubMed Web of Science ®Google Scholar
• Allen DL, Harrison BC, Maass A, et al. Cardiac and skeletal muscle adaptations to voluntary wheel running in the mouse. J Appl Physiol. 2001;90:1900–1908.
   PubMed Web of Science ®Google Scholar
• Luquet S, Lopez-Soriano J, Holst D, et al. Peroxisome proliferator-activated receptor delta controls muscle development and oxidative capability. Faseb J. 2003;17:2299–2301.
   PubMed Web of Science ®Google Scholar
• Jung J-I, Kim J, Hong SK, et al. Long-term follow-up of cutaneous hypersensitivity in rats with a spinal cord contusion. Korean J Physiol Pharmacol. 2008;12:299–306.
   PubMed Web of Science ®Google Scholar
• Moreno S, Farioli-Vecchioli S, Cerù MP. Immunolocalization of peroxisome proliferator-activated receptors and retinoid x receptors in the adult rat CNS. Neuroscience. 2004;123:131–145.
   PubMed Web of Science ®Google Scholar
• Almad A, McTigue DM. Chronic expression of PPAR-δ by oligodendrocyte lineage cells in the injured rat spinal cord. J Comp Neurol. 2010;518:785–799.
   PubMed Web of Science ®Google Scholar
• Onifer SM, Smith GM, Fouad K. Plasticity after spinal cord injury: relevance to recovery and approaches to facilitate it. Neurotherapeutics. 2011;8:283–293.
   PubMed Web of Science ®Google Scholar
• Bareyre FM, Kerschensteiner M, Raineteau O, et al. The injured spinal cord spontaneously forms a new intraspinal circuit in adult rats. Nat Neurosci. 2004;7:269–277.
   PubMed Web of Science ®Google Scholar